LX 6171

Drug Profile

LX 6171

Alternative Names: LX6171

Latest Information Update: 29 Dec 2008

Price : $50

At a glance

  • Originator Lexicon Pharmaceuticals
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action Membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 29 Dec 2008 Discontinued - Phase-II for Cognition disorders in Europe (PO)
  • 07 Dec 2007 Phase-II clinical trials in Cognition disorders in Europe (PO)
  • 02 Aug 2007 Preliminary results from a phase Ib trial in healthy volunteers added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top